<DOC>
	<DOCNO>NCT02919761</DOCNO>
	<brief_summary>2 part multicenter study examine effect Acthar adult subject rheumatoid arthritis ( RA ) persistently active disease . Part 1 Open Label Period eligible subject receive Acthar 12 week . After 12 week treatment Acthar , subject evaluate treatment response use DAS28-ESR . Subjects achieve low disease activity enter double-blind randomized maintenance period ( Part 2 ) randomize 1:1 ratio receive either Acthar match placebo additional 12 week .</brief_summary>
	<brief_title>A Multicenter , 2 Part Study Assess Efficacy Safety H.P . ActharÂ® Gel Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . Subjects must meet criterion rheumatoid arthritis defined 2010 American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) classification screen . 2 . Subjects must persistently active rheumatoid arthritis define DAS 28ESR &gt; 3.2 screening . 3 . Subjects must corticosteroid 12 week prior screen , stable dose 510 mg prednisone ( prednisone equivalent ) 4 week prior screen . 4 . Subjects must either nonbiologic biologic treatment 12 week prior screen . 1 . Subjects use intraarticular steroid within 14 day screen visit . 2 . Subjects know contraindication Acthar . 3 . Subjects Type 1 Type 2 diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>persistant disease activity</keyword>
</DOC>